These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30824647)

  • 1. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
    van der Heijde D; Gladman DD; FitzGerald O; Kavanaugh A; Graham D; Wang C; Fallon L
    J Rheumatol; 2019 Sep; 46(9):1089-1096. PubMed ID: 30824647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
    Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
    Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
    Gladman DD; Coates LC; Wu J; Fallon L; Bacci ED; Cappelleri JC; Bushmakin AG; Helliwell PS
    Arthritis Res Ther; 2022 Feb; 24(1):40. PubMed ID: 35139908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
    Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
    Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
    Dougados M; Taylor PC; Bingham CO; Fallon L; Brault Y; Roychoudhury S; Wang L; Kessouri M
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36814062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J; Deeks ED
    Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
    Landewé R; Ritchlin CT; Aletaha D; Zhang Y; Ganz F; Hojnik M; Coates LC
    Rheumatology (Oxford); 2019 Jun; 58(6):1025-1033. PubMed ID: 30608620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.
    Gladman DD; Mease PJ; Choy EH; Ritchlin CT; Perdok RJ; Sasso EH
    Arthritis Res Ther; 2010; 12(3):R113. PubMed ID: 20537151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
    Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
    Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies.
    van der Heijde D; Landewé RBM; Wollenhaupt J; Strengholt S; Terry K; Kwok K; Wang L; Cohen S
    Rheumatology (Oxford); 2021 Apr; 60(4):1708-1716. PubMed ID: 33057725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.